CytomX Therapeutics Inc (NASDAQ:CTMX) Expected to Post Quarterly Sales of $15.69 Million

Analysts predict that CytomX Therapeutics Inc (NASDAQ:CTMX) will post sales of $15.69 million for the current quarter, Zacks reports. Four analysts have made estimates for CytomX Therapeutics’ earnings. The highest sales estimate is $22.92 million and the lowest is $5.00 million. CytomX Therapeutics posted sales of $11.47 million during the same quarter last year, which suggests a positive year-over-year growth rate of 36.8%. The business is scheduled to announce its next quarterly earnings report on Wednesday, February 26th.

According to Zacks, analysts expect that CytomX Therapeutics will report full year sales of $64.90 million for the current year, with estimates ranging from $54.20 million to $72.13 million. For the next year, analysts forecast that the firm will report sales of $51.05 million, with estimates ranging from $40.00 million to $64.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for CytomX Therapeutics.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CytomX Therapeutics had a negative net margin of 163.18% and a negative return on equity of 90.62%. The business had revenue of $10.71 million for the quarter, compared to analysts’ expectations of $23.58 million.

Several equities research analysts recently weighed in on the company. BidaskClub cut CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 1st. Guggenheim assumed coverage on CytomX Therapeutics in a research note on Wednesday, November 27th. They issued a “buy” rating and a $16.00 price target on the stock. Zacks Investment Research downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 15th. Nomura reissued a “buy” rating and set a $22.00 price objective on shares of CytomX Therapeutics in a research note on Sunday, August 11th. Finally, Wedbush cut shares of CytomX Therapeutics from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $25.00 to $8.00 in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $18.56.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CTMX. First Trust Advisors LP purchased a new position in shares of CytomX Therapeutics during the first quarter valued at approximately $263,000. Strs Ohio boosted its holdings in CytomX Therapeutics by 7.5% in the second quarter. Strs Ohio now owns 59,900 shares of the biotechnology company’s stock valued at $672,000 after acquiring an additional 4,200 shares in the last quarter. Aperio Group LLC purchased a new position in CytomX Therapeutics during the 2nd quarter valued at $70,000. DekaBank Deutsche Girozentrale increased its position in CytomX Therapeutics by 64.6% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 24,200 shares of the biotechnology company’s stock valued at $257,000 after purchasing an additional 9,500 shares during the period. Finally, Candriam Luxembourg S.C.A. raised its holdings in CytomX Therapeutics by 2.8% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 687,833 shares of the biotechnology company’s stock worth $7,684,000 after purchasing an additional 19,000 shares in the last quarter. Institutional investors and hedge funds own 78.89% of the company’s stock.

Shares of CTMX traded up $0.16 during trading hours on Monday, hitting $6.29. The company had a trading volume of 283,934 shares, compared to its average volume of 439,568. CytomX Therapeutics has a 52-week low of $5.10 and a 52-week high of $19.75. The company has a quick ratio of 4.40, a current ratio of 4.40 and a debt-to-equity ratio of 0.31. The stock’s 50 day moving average price is $6.17 and its 200 day moving average price is $8.88. The firm has a market cap of $285.78 million, a P/E ratio of -3.10 and a beta of 0.64.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

See Also: What is the operating income formula?

Get a free copy of the Zacks research report on CytomX Therapeutics (CTMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.